Mirum Pharmaceuticals, Inc. Stock price

Equities

MIRM

US6047491013

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
25.08 USD -0.16% Intraday chart for Mirum Pharmaceuticals, Inc. -3.69% -15.04%
Sales 2024 * 317M Sales 2025 * 420M Capitalization 1.18B
Net income 2024 * -51M Net income 2025 * 33M EV / Sales 2024 * 2.98 x
Net cash position 2024 * 237M Net cash position 2025 * 315M EV / Sales 2025 * 2.06 x
P/E ratio 2024 *
-24.7 x
P/E ratio 2025 *
42.6 x
Employees 264
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.86%
More Fundamentals * Assessed data
Dynamic Chart
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Sector Update: Health Care MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating MT
Mirum Pharmaceuticals Says FDA Approved Familial Intrahepatic Cholestasis Treatment MT
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli DJ
US FDA approves expanded use of Mirum's liver disease drug RE
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis CI
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $40 From $35, Maintains Overweight Rating MT
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024 CI
Transcript : Mirum Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Mirum Pharmaceuticals, Inc. Announces Management Changes CI
Mirum Pharmaceuticals Names Joanne Quan as Chief Medical Officer MT
More news
1 day+1.15%
1 week-2.30%
Current month-11.39%
1 month-11.94%
3 months-15.09%
6 months-19.39%
Current year-13.82%
More quotes
1 week
24.70
Extreme 24.7
26.55
1 month
24.70
Extreme 24.7
30.23
Current year
24.70
Extreme 24.7
30.29
1 year
21.84
Extreme 21.835
35.56
3 years
12.82
Extreme 12.82
35.56
5 years
6.51
Extreme 6.5126
35.56
10 years
6.51
Extreme 6.5126
35.56
More quotes
Managers TitleAgeSince
Founder 45 18-05-06
Founder 71 18-05-06
President 46 20-04-27
Members of the board TitleAgeSince
Director/Board Member 57 23-04-04
Founder 71 18-05-06
Director/Board Member 53 18-11-06
More insiders
Date Price Change Volume
24-03-28 25.08 -0.16% 424 360
24-03-27 25.12 +0.80% 401,405
24-03-26 24.92 -4.67% 462,256
24-03-25 26.14 +0.04% 471,526
24-03-22 26.13 +0.35% 485,046

Delayed Quote Nasdaq, March 28, 2024 at 11:37 am EDT

More quotes
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
25.12 USD
Average target price
49 USD
Spread / Average Target
+95.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Mirum Pharmaceuticals, Inc. - Nasdaq